NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score

被引:8
|
作者
Song, Peng [1 ]
Yang, Dongliang [1 ,2 ]
Cui, Xiaoxia [1 ]
Wang, Hanping [1 ]
Si, Xiaoyan [1 ]
Zhang, Xiaotong [1 ]
Zhang, Li [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp Med, Xinkai Rd, Beijing, Peoples R China
[2] Cangzhou Med Coll, Dept Gen Educ Courses, Beijing, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2020年 / 12卷
关键词
immunotherapy; prognosis score; non-small cell lung cancer; smoking index; TO-LYMPHOCYTE RATIO; NEUTROPHIL-LYMPHOCYTE; TREATED PATIENTS; SOLID TUMORS; OPEN-LABEL; PLATELET; OUTCOMES; CHEMOTHERAPY; METAANALYSIS; SENSITIVITY;
D O I
10.2147/CMAR.S257967
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Currently in China, many immune checkpoint inhibitors (ICIs) have been approved for the treatment of non-small cell lung cancer (NSCLC). Some patients can not benefit from ICIs, and approximately 50% of patients have immunotherapy-related toxicity. Therefore, it is necessary to monitor carefully the selection of immunotherapy population using biomarkers to maximize the benefit of patients with NSCLC. Methods: A prospective analysis was performed on patients with advanced NSCLC who were treated with ICIS at our hospital from March 2018 to June 2019, up to the follow-up deadline of December 31, 2019. The primary end points were overall survival (OS) and progression-free survival (PFS), and the secondary end points were objective response rate and disease control rate. A lasso regression was used for the univariate analysis, and Cox regression analysis was used for the multivariate analysis. An efficacy prediction line chart was developed. Results: A total of 63 patients were included in the study. The median PFS was 7.0 months (95% CI, 5.0-11.0) and did not reach the median OS. According to the lasso regression, significant univariate factors were smoking index, PD-ligand 1 expression, and neutrophil to lymphocyte ratio (NLR). According to the multivariate analysis, the Cox proportional hazards model showed that smoking index and NLR are independent predictors of PFS in immunotherapy. A model comprised of independent predictors was developed based on a multivariate logical analysis of the main cohort-non-small cell lung cancer immunotherapy prognosis score. This model is shown as a nomogram with a C-index of 0.801 (95% CI, 0.744, 0.858), which has high prediction accuracy. Conclusion: This predictive model, including NLR and smoking index, can achieve a 1-year PFS in immunotherapy of patients. PD-1 inhibitors have been demonstrated to be effective and safe in the clinical treatment of patients with NSCLC.
引用
收藏
页码:5975 / 5985
页数:11
相关论文
共 50 条
  • [41] THE SOCIAL VALUE OF IMMUNOTHERAPY IN NON-SMALL CELL LUNG CANCER
    Sullivan, J.
    Ward, Sexton A.
    Korytowsky, B.
    Peneva, D.
    Benner, J.
    Lakdawalla, D. N.
    Bolinder, B.
    Figlin, R. A.
    Jena, A. B.
    VALUE IN HEALTH, 2016, 19 (03) : A167 - A167
  • [42] Immunotherapy in surgically resectable non-small cell lung cancer
    Owen, Dwight
    Chaft, Jamie E.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S404 - S411
  • [43] Immunotherapy through the Lens of Non-Small Cell Lung Cancer
    Stanley, Robyn
    Flanagan, Saoirse
    O'Reilly, David
    Kearney, Ella
    Naidoo, Jarushka
    Dowling, Catriona M.
    CANCERS, 2023, 15 (11)
  • [44] Biomarkers for immunotherapy resistance in non-small cell lung cancer
    Rother, Catriona
    John, Tom
    Wong, Annie
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [45] First line Immunotherapy for Non-Small Cell Lung Cancer
    Nasser, Nicola J.
    Gorenberg, Miguel
    Agbarya, Abed
    PHARMACEUTICALS, 2020, 13 (11) : 1 - 24
  • [46] Current status of immunotherapy for non-small cell lung cancer
    Yang, Tao
    Xiong, Yilin
    Zeng, Yufei
    Wang, Yan
    Zeng, Jing
    Liu, Jie
    Xu, Shangfu
    Li, Li-Sheng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [47] Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
    Lochrin, Sarah E.
    Forde, Patrick M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (08) : 415 - 423
  • [48] Current state of immunotherapy for non-small cell lung cancer
    Malhotra, Jyoti
    Jabbour, Salma K.
    Aisner, Joseph
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (02) : 196 - 211
  • [49] Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
    Garon, Edward B.
    SEMINARS IN ONCOLOGY, 2015, 42 (05) : S11 - S18
  • [50] Immunotherapy in oncogene addicted non-small cell lung cancer
    McLean, Luke
    Leal, Jose Luis
    Solomon, Benjamin J.
    John, Thomas
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2736 - 2751